Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis

Expert Review of Cardiovascular Therapy

Volumn 1, Issue 2, 2003, Pages 257-269

  Bonnefoy, Arnaud ^a   Vermylen, Jos ^a   Hoylaerts, Marc f ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

animal model; antiplatelet therapy; gain of function mutation; GPIb ; platelet receptor; thrombosis; von Willebrand disease; von Willebrand factor

Indexed keywords

ANTITHROMBOCYTIC AGENT; THROMBIN RECEPTOR; VON WILLEBRAND FACTOR;

CORONARY ARTERY THROMBOSIS; DRUG EFFECT; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSIOLOGY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ARTERIAL OCCLUSIVE DISEASES; CORONARY THROMBOSIS; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; VON WILLEBRAND FACTOR;

EID: 2142718259     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.1.2.257     Document Type: Review

References (95)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349, 1269 – 1276 (1997).
2. Gersh BJ. Current issues in reperfusion therapy. Am. j Canliol. 82,3P-11P (1998).
3. Topol EJ, Byzova TV, Plow EE Platelet GPIIb-IIIa blockers. Lancet 353 (9148), 227 – 231 (1999).
4. Aronow HD, Topol EJ. Antiplatelet therapy in cardiology. In: Platelets in Thrombotic and Non-thrombotic Disonlers: Gresele P, Page C, Fuster V, Vermylen J (Eds). Cambridge University Press, Cambridge, UK (2002).
5. Rajagopalan V, Essex DW, Shapiro SS, Konlde BA. Tumor necrosis factor-a modulation of glycoprotein Iba expression in human endothelial and erythroleukemia cells. B/ooc/ 80, 153 – 161 (1992).
6. Huizinga EG, Tsuji S, Romijn RA et al Structures of glycoprotein Iba and its complex with von Willebrand factor Al domain. Science 297, 1176 – 1179 (2002).
7. Shen Y, Romo GM, Dong JF et al Requirement of leucine-rich repeats of glycoprotein (GP) Iba for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. B/ooc/ 95, 903 – 910 (2000).
8. Williamson D, Pikovski I, Cranmer SL et al Interaction between platelet glycoprotein Iba and filamin-1 is essential for glycoprotein Ib/IX receptor anchorage at high shear. j Biol. Chem. 277, 2151 – 2159 (2002).
9. Yap CL, Hughan SC, Cranmer SL et al Synergistic adhesive interactions and signaling mechanisms operating between platelet glycoprotein Ib/IX and integrin allb13 3. Studies in human platelets and transfected Chinese hamster ovary cells.1. Biol. Chem. 275,41377-41388 (2000).
10. Andrews RK, Munday AD, Mitchell CA, Berndt MC. Interaction of calmodulin with the cytoplasmic domain of the platelet membrane glycoprotein Ib-IX-V complex. B/ooc/ 98, 681 – 687 (2001).
11. Wu Y, Asazuma N, Satoh K et al Interaction between von Willebrand factor and glycoprotein Ib activates Src kinase in human platelets: role of phosphoinositide 3-kinase. Blood 101,3469-3476 (2003).
12. Hayashi T, Suzuki K. Molecular pathogenesis of Bernard–Soulier syndrome. Semin. Thromb. Hemost. 26, 53 – 59 (2000).
13. Tait AS, Cranmer SL, Jackson SP, Dawes IW, Chong BH. Phenotype changes resulting in high-affinity binding of von Willebrand factor to recombinant glycoprotein Ib—IX: analysis of the platelet-type von Willebrand disease mutations. B/ooc/ 98, 1812 – 1818 (2001).
14. Nachman R, Levine R, Jaffe EA. Synthesis of Factor VIII antigen by cultured guinea-pig megakaryocytes. j Clin. Invest. 60, 914 – 9921 (1977).
15. Jaffe EA, Hoyer LW Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Pmc. Nat! Acad. Sci. USA 71, 1906 – 1909 (1974).
16. Shelton-Inloes BB, Titani K, Sadler JE. cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms. Biochemistry 25, 3164 – 3171 (1986).
17. Romijn RA, Westein E, Bouma B et al Mapping the collagen-binding site in the von Willebrand factor A3-domain. j Biol. Chem. 278, 15035 – 15039 (2003).
18. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand Factor Al domain and implications for the binding of platelet glycoprotein Ib. j Biol. Chem. 273, 10396 – 10401 (1998).
19. Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. B/ooc/91, 2032 -2044 (1998).
20. Perkins SJ, Smith KF, Williams SC, Hans PI, Chapman D, Sim RB. The secondary structure of the von Willebrand factor type A domain in factor B of human complement by Fourier transform infrared spectroscopy. Its occurrence in collagen types VI, VII, XII and XIV, the integrins and other proteins by averaged structure predictions. j Mal Biol. 238, 104 – 119 (1994).
21. Sugimoto M, Mohri H, McClintock RA, Ruggeri ZM. Identification of discontinuous von Willebrand factor sequences involved in complex formation with botrocetin. j Biol. Chem. 266, 18172 – 18178 (1991).
22. Celikel R, Varughese KT, Madhusudan, Yoshioka A, Ware J, Ruggeri ZM. Crystal structure of the von Willebrand factor Al domain in complex with the function blocking NMC-4 Fab. Nat. Struct. Biol. 5, 189 – 194 (1998).
23. Vasudevan S, Roberts JR, McClintock RA et al Modeling and functional analysis of the interaction between von Willebrand factor Al domain and glycoprotein Iba.1. Biol. Chem. 275,12763-12768 (2000).
24. Matsushita T, Meyer D, Sadler JE. Localization of von Willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. j Biol. Chem. 275, 11044 – 11049 (2000).
25. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. Mapping the glycoprotein Ib-binding site in the von Willebrand factor Al domain. j Biol. Chem. 275, 19098 – 19105 (2000).
26. Bonnefoy A, Yamamoto H, Thys C, Kito M, Vermylen J, Hoylaerts ME. Shielding the front-strand 133 of the von Willebrand factor Al domain inhibits its binding to platelet glycoprotein Iba. Blood 101, 1375 – 1383 (2003).
27. Pietu G, Fressinaud E, Girma JP, Nieuwenhuis HK, Rothschild C, Meyer D. Binding of human von Willebrand factor to collagen and to collagen-stimulated platelets. j Lab. Clin. Med. 109, 637 – 646 (1987).
28. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of Type IIA von Willebrand disease mutations. j Biol. Chem. 267, 4424 – 4430 (1992).
29. Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann. Rev Biochem. 67, 395 – 424 (1998).
30. Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb—IIIa (integrin a11,133) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. j Biol. Chem. 267, 11300 – 11306 (1992).
31. Ni H, Denis CV, Subbarao S et al Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. j Clin. Invest 106, 385 – 392 (2000).
32. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Ce1184, 289 – 297 (1996).
33. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. B/ooc/ 88, 2939 – 2950 (1996).
34. Smith DE, Babcock HP, Chu S. Single-polymer dynamics in steady shear flow. Science 283 (5408), 1724 – 1727 (1999).
35. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann. Hematol 72, 341 – 348 (1996).
36. Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. Blood 101, 2637 – 2645 (2003).
37. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96, 1102 – 1108 (1997).
38. Goto S, Sakai H, Goto M et al Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 99, 608 – 613 (1999).
39. Bosmans JM, Kockx MM, Vrints CJ, Bult H, De Meyer GR, Herman AG. Fibrin(ogen) and von Willebrand factor deposition are associated with intimal thickening after balloon angioplasty of the rabbit carotid artery. Arterioscler. Thromb. Vasc. Biol. 17, 634 – 645 (1997).
40. De Meyer GR, Hoylaerts ME, Kockx MM, Yamamoto H, Herman AG, Bult H. Intimal deposition of functional von Willebrand factor in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 19, 2524 – 2534 (1999).
41. Qin F, Dardik H, Pangilinan A, Robinson J, Chuy J, Wengerter K. Remodeling and suppression of intimal hyperplasia of vascular grafts with a distal arteriovenous fistula in a rat model. j Vasc. Surg. 34, 701 – 706 (2001).
42. Theilmeier G, Michiels C, Spaepen E et al Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. B/ooc/99, 4486 – 4493 (2002).
43. Theilmeier G, Lenaerts T, Remade C, Collen D, Vermylen J, Hoylaerts ME. Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress. Blood 94, 2725 – 2734 (1999).
44. Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 98, 1424 – 1428 (2001).
45. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. j Clin. Invest. 78, 1456 – 1461 (1986).
46. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. B/ooc/87, 4223 – 4234 (1996).
47. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. B/ooc/ 87, 4235 – 4244 (1996).
48. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in Type IIA von Willebrand factor. Proc. Natl Acad. Li. USA 87, 6306 – 6310 (1990).
49. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 83, 2171 – 2179 (1994).
50. Dong JF, Moake JL, Nolasco L et al ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100, 4033 – 4039 (2002).
51. Moake JL, Rudy CK, Troll JH et al Unusually large plasma Factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. Med. 307, 1432 – 1435 (1982).
52. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixrna JJ, Nagel RL. Proteolytic cleavage of recombinant Type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blooc189, 1954 -1962 (1997).
53. Savage B, Sixrna JJ, Ruggeri ZM. Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc. Natl Acad. Li. USA 99, 425 – 430 (2002).
54. Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. I Exp. Med 193, 1341 – 1349 (2001).
55. Dong JF, Bernardo A, Nolasco L, Padilla A, Moake J, Lopez J. Proteolysis of ultra-large von Willebrand Factor multimers on the endothelial surface requires protease docking and is inhibited by thrombospondin-1. Annual American Society for Hematology Philidelphia, PA, USA (2002) (Abstract 457).
56. Gralnick HR, Williams S, McKeown L et al A monomeric von Willebrand factor fragment, Leu-504—Lys-728, inhibits von Willebrand factor interaction with glycoprotein lb-TX [coryeeted]. f3vc Nat! Acad. Li USA 89,7880-7884 (1992). Erratum in: Proc. Natl. Acad. Sci. USA 90, 3118 (1993).
57. Andre P, Hamaud P, Bal dit Sollier C et al Guinea-pig blood: a model for the pharmacologic modulation of the GPIb/IX-vWF axis. Thromb. Res. 83, 127 – 136 (1996).
58. Yao SK, Ober JC, Garfinkel LI et al Blockade of platelet membrane glycoprotein lb receptors delays intracoronary thrombogenesis, enhances thrombolysis and delays coronary artery reocdusion in dogs. Ciaulation 89, 2822 – 2828 (1994).
59. McGhie AI, McNatt J, Ezov N et al Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein lb binding domain. Circulation 90, 2976 – 2981 (1994).
60. Zahger D, Fishbein MC, Garfinkel LI et al VCL, an antagonist of the platelet GPlb receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Ciaulation 92, 1269 – 1273 (1995).
61. Cauwenberghs N, Vanhoorelbeke K, Vauterin SN et al Epitope mapping of inhibitory antibodies against platelet glycoprotein Iba reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Iba. B/ooc/98, 652 – 660 (2001).
62. Miller JL. Platelet-type von Willebrand disease. Thmmh I-Lemost. 75, 865 – 869 (1996).
63. Wu D, Vanhoorelbeke K, Cauwenberghs N et al Inhibition of the von Willebrand (vWF) -collagen interaction by an antihuman vWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. B/ooc/ 99, 3623 – 3628 (2002).
64. Ward CM, Andrews RK, Smith AI, Berndt MC. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Iba. Identification of the sulfated tyrosine/anionic sequence Tyr-276—Glu-282 of glycoprotein Iba as a binding site for von Willebrand factor and a-thrombin. Biochemistry 35, 4929 – 4938 (1996).
65. De Luca M, Dunlop LC, Andrews RK et al A novel cobra venom metalloproteinase, mocarhagin, cleaves a 10-amino acid peptide from the mature N terminus of P-selectin glycoprotein ligand receptor, PSGL-1 and abolishes P-selectin binding. J. Biol. Chem. 270, 26734 – 26737 (1995).
66. Lefer AM, Campbell B, Shin YK. Effects of a metalloproteinase that truncates P-selectin glycoprotein ligand on neutrophil-induced cardiac dysfunction in ischaemia/reperfusion. j Mal Cell Can:hal 30, 2561 – 2566 (1998).
67. Chang MC, Lin HK, Peng HC, Huang TE Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Gratalus atrox. BloocI 91, 1582 – 1589 (1998).
68. Wu WB, Peng HC, Huang TE Crotalin, a vWF and GP Ib cleaving metalloproteinase from venom of Gratalus atrox. Thromb. kkemost. 86, 1501 – 1511 (2001).
69. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Antithrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. BE J. Pharmacol 122, 165 – 171 (1997).
70. Eto K, Isshiki T, Yamamoto H et al AJvW-2, an antivWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 19, 877 – 882 (1999).
71. Poletti LF, Bird K, Harris RB, Marques D, Sobel M. Prevention of arterial thrombosis using a novel heparin with enhanced antiplatelet activity and reduced anticoagulant activity. J. Vasc. Surg. 26, 366 – 372 (1997).
72. Yamamoto H, Vreys I, Stassen JM, Yoshimoto R, Vermylen J, Hoylaerts MF. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb.themost. 79, 202 – 210 (1998).
73. Kageyama S, Yamamoto H, Nakazawa H, Yoshimoto R. Antihuman vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb. Res. 101, 395 – 404 (2001).
74. Kageyama S, Yamamoto H, Yoshimoto R. Antihuman von Willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea-pigs. Arterioscler. Thromb. Vasc. Biol. 20, 2303 – 2308 (2000).
75. Bellinger DA, Nichols TC, Read MS et al Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc. Natl Acad. Sci. USA 84, 8100 – 8104 (1987).
76. Weinstein M, Vosburgh E, Phillips M, Turner N, Chute-Rose L, Moake J. Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib. Comparison with other polyanionic and polyaromatic polymers. B/ooc/ 78, 2291 – 2298 (1991)
77. Strony J, Phillips M, Brands D, Moake J, Adelman B. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation 81, 1106 – 1114 (1990).
78. Strony J, Song A, Rusterholtz L, Adelman B. Aurintricarboxylic acid prevents acute rethrombosis in a canine model of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 15, 359 – 366 (1995).
79. Azzam K, Cisse-Thiam M, Drouet L. The antithrombotic effect of aurin tricarboxylic acid in the guinea-pig is not solely due to its interaction with the von Willebrand factor-GPIb axis. Thromb.themost. 75, 203 – 210 (1996).
80. Golino P, Ragni M, Cirillo P et al Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Thromb.themost. 74, 974 – 979 (1995).
81. Kinlough-Rathbone RL, Packham MA. Unexpected effects of aurin tricarboxylic acid on human platelets. Thromb. Haemost. 68, 189 – 193 (1992).
82. Matsuno H, Kozawa 0, Niwa M, Uematsu T Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation 96, 1299 – 1304 (1997).
83. Hoylaerts ME, Nuyts K, Peerlinck K, Deckmyn H, Vermylen J. Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin. Biochem.j 306, 453 – 463 (1995).
84. Depraetere H, Viaene A, Deroo S, Vauterin S, Deckmyn H. Identification of peptides, selected by phage display technology, that inhibit von Willebrand factor binding to collagen. B/ooc/ 92, 4207 – 4211 (1998).
85. Barnes CS, Krafft B, Frech M et al Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen. Semin. Thmmb. Hemost. 27, 337 – 348 (2001).
86. Cruz CP, Eidt J, Drouilhet J et al Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. Vasc. Surg. 34, 724 – 729 (2001).
87. Goto S, Tamura N, Handa S, Arai M, Kodama K, Takayama H. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation 106, 266 – 272 (2002).
88. Deckmyn H, Stassen JM, Vreys I, Van Houtte E, Sawyer RT, Vermylen J. Calmn from Ifirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters. Blood 85, 712 – 719 (1995).
89. Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C. Cloning, expression analysis and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 283, 49 – 62 (2002).
90. Kuwahara M, Sugimoto M, Tsuji S, Miyata S, Yoshioka A. Cytosolic calcium changes in a process of platelet adhesion and cohesion on a von Willebrand factor-coated surface under flow conditions. Blood 94, 1149 – 1155 (1999).
91. Nesbitt WS, Kulkarni S, Giuliano S et al Distinct glycoprotein IbN/IX and integrin a11b133-dependent calcium signals co-operatively regulate platelet adhesion under flow. Bio/. Chem. 277, 2965 – 2972 (2002).
92. Mazzucato M, Pradella P, Cozzi MR, De Marco L, Ruggeri ZM. Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Iba mechanoreceptor. Blood 100, 2793 – 2800 (2002).
93. Nesbitt WS, Giuliano S, Kulkarni S, Dopheide SM, Harper IS, Jackson SR Intercellular calcium communication regulates platelet aggregation and thrombus growth. 1 Cell Biol. 160,1151-1161 (2003).
94. Tait AS, Dong JF, Lopez JA, Dawes IW, Chong BH. Site-directed mutagenesis of platelet glycoprotein Iba demonstrating residues involved in the sulfation of tyrosines 276,278 and 279. B/ooc/99, 4422 – 4427 (2002).
95. Afshar-Kharghan V, Gineys G, Schade AJ et al Necessity of conserved asparagine residues in the leucine-rich repeats of platelet glycoprotein Iba for the proper conformation and function of the ligand-binding region. Biochemistry 39, 3384 – 3391 (2000).